SCHEMBL2894151

SCHEMBL2894151

CC(C)Oc1ncccc1CO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
SLC13A5 Q86YT5 1/20 0.52
LIPG Q9Y5X9 1/20 0.48
FFAR4 Q5NUL3 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 1/20 0.40
KDM4E B2RXH2 3/20 0.39
NPC1 O15118 2/20 0.39
HTT P42858 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
ALOX5AP P20292 2/20 0.37
FEN1 P39748 2/20 0.37
LRRK2 Q5S007 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13361871 0.84 SLC13A5 (0.53) MEN1KMT2ASLC13A5LIPGFFAR4
SCHEMBL29630263 0.82 MEN1 (0.51) MEN1KMT2ASLC13A5LIPGL3MBTL1
SCHEMBL4477933 0.82 SLC13A5 (0.49) MEN1KMT2ASLC13A5LIPGFFAR4
SCHEMBL31475001 0.82 SLC13A5 (0.52) MEN1KMT2ASLC13A5LIPGFFAR4
SCHEMBL30912121 0.82 SLC13A5 (0.49) MEN1KMT2ASLC13A5LIPGFFAR4
SCHEMBL23286941 0.82 MEN1 (0.51) MEN1KMT2ASLC13A5LIPGL3MBTL1
SCHEMBL18440 0.79 MEN1 (0.60) MEN1KMT2ASLC13A5L3MBTL1ALDH1A1
SCHEMBL31365171 0.79 MEN1 (0.60) MEN1KMT2ASLC13A5L3MBTL1ALDH1A1
SCHEMBL12776099 0.79 SLC13A5 (0.50) MEN1KMT2ASLC13A5LIPGFFAR4
Hydrochloric Acid SCHEMBL5900888 0.78 MEN1 (0.58) MEN1KMT2ASLC13A5L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112654621-B Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2024-05-14 CN disclosed
CN-112654621-A Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2021-04-13 CN disclosed
EP-2098517-B1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE MSD KK (JP) 2013-12-18 EP disclosed
US-8367708-B2 Phenyl-isoxazol-3-ol derivative MSD K.K. (JP) 2013-02-05 US disclosed
US-20100130559-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
EP-2098517-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130559-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE GPR119, FFAR3, FFAR2 MEN1 4777/4885KMT2A 1822/4885SLC13A5 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.